Tyra prices $400 million stock and pre-funded warrant offering
Tyra Biosciences announced a $400 million underwritten offering of common stock and pre-funded warrants. The financing expands the company’s capital base but creates near-term dilution pressure for existing shareholders.
PR NEWSWIRE / FILEThe story
Tyra Biosciences said on Sept. 14 that it priced an underwritten offering combining common stock with pre-funded warrants, with gross proceeds of $400 million before underwriting discounts and offering expenses. The announcement identified the issuer as Tyra Biosciences, a clinical-stage company developing precision medicines focused on FGFR biology.
The transaction is a financing event rather than a clinical or regulatory update. The specific number of common shares and pre-funded warrants issued, the offering price, the expected net proceeds, and the allocation of the funds remain to be disclosed in final offering documents.
The immediate connection is to TYRA's capital structure: newly issued common stock increases the share count, while pre-funded warrants can also become common stock subject to their terms. The proceeds give the company additional cash to fund its development programs.
The size of the financing is clear, but the terms needed to quantify dilution will be established in the final offering documents and subsequent securities filings, which should establish the securities issued, pricing, warrant terms, underwriting costs, and the company's post-transaction share count.
Our read · Mon, Sep 14
The $400 million financing strengthens TYRA’s runway but puts near-term pressure on existing holders through new equity and warrant issuance.
Why. The financing improves TYRA's funding capacity for its clinical-stage pipeline, but the equity and pre-funded warrant structure makes dilution the immediate offset. The read should remain balanced until the final prospectus and subsequent filing establish the post-offering share count, warrant terms, net proceeds, and updated cash position.
Both cases
What could change this view: The trade read changes if the final documents show materially favorable pricing, limited incremental share issuance, or a clearly disclosed funding runway that reduces near-term financing risk.
Who reported it · 1
Keep reading
Latest on the Wire
German producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinue on the Wire →Latest on the Wire
Continuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandTrump, Xi and Putin pledge more refined fuel after first trilateral summitContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by PR Newswire as Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →